Rademikibart IV for Acute Asthma and COPD Exacerbation

Part of paid clinical trials in Miami, Florida.

Sponsor
Connect Biopharm LLC
Study ID
NCT07705737
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Asthma Acute
  • COPD Exacerbation Acute

Eligibility Criteria

Sex
ALL
Age
18 Years - 85 Years
Healthy Volunteers
Not accepted

Interventions

  • Rademikibart — DRUG
    Single 300 mg dose as a 2-minute IV push

Study Details

A Phase 2, open-label, single-arm trial to evaluate IV rademikibart as an add-on treatment for acute exacerbation in participants with asthma or COPD with type 2 inflammation

Key Dates

First listed
Jul 15, 2026
Start date
Aug 21, 2026
Status verified
Aug 2026
Primary completion
Dec 31, 2026
Completion
Jan 31, 2027

Study Design

Enrollment
40 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Rademikibart

Primary Outcome Measure

Change from baseline in post-BD FEV1 [ Time Frame: 1 week ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Columbus Clinical Services, LLCMiamiFlorida33135
Radha Adivikolanu
[email protected]
213-522-7990
Pharmax Research of South Florida, Inc.MiamiFlorida33175
Radha Adivikolanu
[email protected]
213-522-7990

Find similar trials in Miami, FL

By research site
Columbus Clinical Services, LLC· Miami, FLPharmax Research of South Florida, Inc.· Miami, FL

Related Studies